CriticalAntiepileptics. Carboxamide derivatives×Atypical antipsychotic – dibenzodiazepine
Updated · Methodology
Mechanism
Clozapine can cause agranulocytosis, a sharp fall in neutrophils (Spanish clozapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). Carbamazepine has been associated with cases of agranulocytosis and aplastic anaemia (carbamazepine SmPC, AEMPS, section 4.4). The clozapine SmPC lists carbamazepine among drugs that suppress the bone marrow. Taken with clozapine, these drugs increase the risk or severity of bone marrow suppression (AEMPS, section 4.5). The second mechanism is enzyme induction. Carbamazepine strongly induces CYP3A4 (carbamazepine SmPC, AEMPS, section 4.5). CYP1A2 and CYP3A4 metabolise almost all of the clozapine in the liver, so clozapine levels and effectiveness can fall (Spanish clozapine SmPC, AEMPS, sections 4.5 and 5.2). After carbamazepine is stopped, clozapine levels can rise, and so can the risk of adverse reactions (US Clozaril label, US Food and Drug Administration, FDA, section 7.1). The US clozapine label also says that clozapine can raise the levels of drugs metabolised by CYP2D6 and names carbamazepine among them (FDA, section 7.2).
Symptoms
Agranulocytosis presents with fever, sore throat, flu-like symptoms and other signs of infection (Spanish clozapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). People taking carbamazepine are warned about the early signs of a possible blood, skin or liver problem: fever, sore throat, rash, mouth ulcers, easy bruising, petechiae and purpura (carbamazepine SmPC, AEMPS, section 4.4). Induction can make clozapine less effective. After carbamazepine is stopped, clozapine levels can rise, and so can the risk of adverse reactions. These include seizures, whose risk depends on the dose (US Clozaril label, US Food and Drug Administration, FDA, sections 5.4 and 7.1).
Management
The combination is contraindicated (Spanish clozapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). Clozapine must not be started together with substances known to have a substantial potential to cause agranulocytosis or used with bone marrow suppressants. Carbamazepine is explicitly named in that list. The US Food and Drug Administration (FDA) also does not recommend combining clozapine with strong CYP3A4 inducers, including carbamazepine (US Clozaril label, FDA, sections 2.7 and 7.1). If a patient is nevertheless taking both drugs, the FDA suggests considering more frequent absolute neutrophil count (ANC) monitoring than the standard schedule (US Clozaril label, FDA, section 5.1). The clozapine dose is adjusted to clinical need (carbamazepine SmPC, AEMPS, section 4.5). If fever, sore throat or other signs of infection appear, a differential white cell count is done at once (Spanish clozapine SmPC, AEMPS, section 4.4). At a temperature of 38.5 °C or higher, clozapine is interrupted and an ANC is obtained (US Clozaril label, FDA, section 5.1). If the ANC is below 1000/mm³ (below 500/mm³ in benign ethnic neutropenia), clozapine is stopped at once and the count is repeated daily. The patient is not re-exposed to clozapine (Spanish clozapine SmPC, AEMPS, section 4.4). If there is evidence of significant bone marrow depression, carbamazepine is stopped (carbamazepine SmPC, AEMPS, section 4.4). When carbamazepine is stopped, consider lowering the clozapine dose, because clozapine levels and the risk of adverse reactions can rise (US Clozaril label, FDA, section 7.1).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Carbamazepina (nº registro 39955), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 39955, revisión 09/2026, secciones 4.4 y 4.5
- FDA: Tegretol (carbamazepine) prescribing information (2026)– FDA label, DailyMed setid 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053, version 39, revised 08/2026, Contraindications and PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Clozapina – Leponex (nº registro 59547), sección 4.5 (2026)– AEMPS, CIMA, nº registro 59547, revisión 06/2026, secciones 4.4 y 4.5
- FDA: Clozaril (clozapine) prescribing information (2025)– FDA, DailyMed, HLS Therapeutics, setid 90876802-0e3a-44c9-9ff7-1754dfbe736a, v21, 06/2025, sections 5.1, 5.4, 5.5, 7.1
- AEMPS: Ficha técnica: Clozapina (nº registro 59547), sección 4.3 (2026)– AEMPS, CIMA, nº registro 59547 (Leponex 100 mg comprimidos), revisión 06/2026, sección 4.3
- AEMPS: Ficha técnica: Clozapina (nº registro 59547), sección 4.4 (2026)– AEMPS, CIMA, nº registro 59547 (Leponex 100 mg comprimidos), revisión 06/2026, secciones 4.3 y 4.4
- AEMPS: Ficha técnica: Clozapina (nº registro 59547), secciones 4.9 y 5.2 (2026)– AEMPS, CIMA, nº registro 59547 (Leponex 100 mg comprimidos, Viatris), revisión 06/2026, secciones 4.9 y 5.2